Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent
ZacksRegeneron’s (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.
Regeneron’s (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.